- Home
- MGIC vs GHRS Comparison
MGIC vs GHRS Comparison
Compare MGIC & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGIC
- GHRS
- Stock Information
- Founded
- MGIC 1983
- GHRS 2018
- Country
- MGIC Israel
- GHRS Ireland
- Employees
- MGIC N/A
- GHRS N/A
- Industry
- MGIC Computer Software: Prepackaged Software
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- MGIC Technology
- GHRS Health Care
- Exchange
- MGIC Nasdaq
- GHRS Nasdaq
- Market Cap
- MGIC 788.0M
- GHRS 849.8M
- IPO Year
- MGIC 1991
- GHRS 2021
- Fundamental
- Price
- MGIC $16.98
- GHRS $12.31
- Analyst Decision
- MGIC Buy
- GHRS Strong Buy
- Analyst Count
- MGIC 2
- GHRS 8
- Target Price
- MGIC $16.00
- GHRS $30.63
- AVG Volume (30 Days)
- MGIC 60.5K
- GHRS 187.6K
- Earning Date
- MGIC 08-13-2025
- GHRS 05-08-2025
- Dividend Yield
- MGIC 3.32%
- GHRS N/A
- EPS Growth
- MGIC 1.33
- GHRS N/A
- EPS
- MGIC 0.76
- GHRS N/A
- Revenue
- MGIC $569,136,000.00
- GHRS N/A
- Revenue This Year
- MGIC $7.53
- GHRS N/A
- Revenue Next Year
- MGIC $8.96
- GHRS N/A
- P/E Ratio
- MGIC $22.08
- GHRS N/A
- Revenue Growth
- MGIC 6.37
- GHRS N/A
- 52 Week Low
- MGIC $9.51
- GHRS $6.00
- 52 Week High
- MGIC $17.07
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- MGIC 65.74
- GHRS 52.37
- Support Level
- MGIC $15.02
- GHRS $12.43
- Resistance Level
- MGIC $17.07
- GHRS $13.15
- Average True Range (ATR)
- MGIC 0.36
- GHRS 0.99
- MACD
- MGIC 0.01
- GHRS -0.14
- Stochastic Oscillator
- MGIC 95.61
- GHRS 41.03
About MGIC Magic Software Enterprises Ltd.
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.